^
    CANCER:

    Osteosarcoma





    Show legend
    Group by Gene:
    Include preclinical:

    regorafenib
    		0
    Multi-tyrosine kinase inhibitor
    cabozantinib tablet
    anlotinib
    1
    DNA synthesis inhibitor
    gemcitabine
    cisplatin
    2
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    3
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate
    4
    Tubulin polymerization promoter, Alkylating agent
    carboplatin + cyclophosphamide
    5
    Bifunctional alkylating agent, Tubulin polymerization promoter
    carboplatin + ifosfamide
    6
    Bifunctional alkylating agent
    ifosfamide
    7
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    8
    Macrophage stimulant, Monocyte stimulant
    mifamurtide
    9
    PD-L1 inhibitor
    STI-A1014
    10
    PD1 inhibitor
    pembrolizumab
    11
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    12
    ALK inhibitor
    crizotinib
    13
    LSD1 inhibitor
    SP2577
    14
    Chemotherapy
    MAP
    IE
    15
    IGF-1R inhibitor
    IGF-1R inhibitor
    16
    Alkylating agent, Topoisomerase I inhibitor
    cyclophosphamide + topotecan
    17
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    18
    THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor
    cisplatin + doxorubicin hydrochloride + methotrexate
    19
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + doxorubicin hydrochloride
    20
    Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA inhibitor, Dihydrofolic acid reductase inhibitor
    ifosfamide + methotrexate + etoposide oral
    21
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + ifosfamide + pegylated liposomal doxorubicin
    22
    Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor
    cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
    23
    Bifunctional alkylating agent, Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + ifosfamide + etoposide IV
    24
    Bifunctional alkylating agent, Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
    gemcitabine + docetaxel + ifosfamide
    25
    Topoisomerase II inhibitor, Alkylating agent
    cyclophosphamide + etoposide IV
    26
    Topoisomerase II inhibitor, Tubulin polymerization promoter, Alkylating agent
    carboplatin + cyclophosphamide + etoposide IV
    27
    Microtubule stabilizer, Tubulin polymerization promoter, Alkylating agent, DNA synthesis inhibitor
    gemcitabine + docetaxel + cyclophosphamide
    28
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
    gemcitabine + docetaxel
    29
    pan-RAF inhibitor, mTOR inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + everolimus
    30
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, CDK4 inhibitor, CDK6 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    palbociclib + lenvatinib
    31
    CSF-1R inhibitor
    ABSK021
    32
    Reactive oxygen species stimulant, Photosensitizer
    verteporfin
    No biomarker
    MSI-H/dMMR
    PGP overexpression
    CDK4 amplification
    PGP expression
    CDK4 overexpression
    NTRK2 fusion
    TMB-H
    NTRK1 fusion
    NTRK3 fusion
    XPC K939G
    TAF15-CHN1 translocation
    KANK1-NTRK2 fusion
    PDGFRB overexpression
    KDR overexpression
    KDR overexpression + PDGFRB overexpression
    PD-L1 expression
    KDM1A overexpression
    MALAT1 overexpression
    TP53 deletion + RB1 deletion + CTSK expression
    ERCC1 K504Q
    CSF1R overexpression
    EGFR overexpression
    ABCG2 overexpression
    ERCC2 D312N
    IGF1R expression
    RB1 positive
    ERCC1 N118N
    ERCC2 K751G